CTOR Company Profile and Key Details

Citius Oncology, Inc. has 78.37 million shares outstanding. The public float is 16.37 million shares, elevated short interest at 2.46% of float. This equals 303.36 thousand shares. The short ratio is 0.84 days. Institutional investors hold 5.71% of the float. Insiders own 86.83%.

CTOR has shown mixed momentum, losing -1.87% over the past week and -38.24% over the past quarter, though year-to-date performance is up 5.0%. Short-term trend indicators are mixed aligned (SMA20 -3.88%, SMA50 -3.19%, SMA200 -32.83%). The stock’s 14-day RSI is 43.99 (neutral), while the ATR of 0.08 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -82.39% below its high and over 97.97% above its low. Average 10-day trading volume of 111.56 thousand shares is below the 3-month average of 170.83 thousand, indicating normal recent market interest.

Citius Oncology, Inc. generated EPS of -$0.31 over the past year. Five-year average earnings growth is -309.67%. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers 566.67% upside. The low target suggests 566.67% downside. The mean target is $6.00. This offers 566.67% upside. Citius Oncology, Inc. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended February 13, 2026, missed forecasts by 50.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 50.0% in February 14, 2025.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently mid-range between its 52-week high and low $0.49 and $6.19. With a market capitalization of about $79.87 million, Citius Oncology, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.57). Key stats such as the average daily volume over the past year has been around 242.79 thousand shares, volume is running light vs its 52-week average. Headquartered in New York City, NY, Citius Oncology, Inc. operates in the Healthcare sector and the Drug Manufacturers - General industry. Led by CEO Leonard L. Mazur, the company employs approximately 285 people and listed since December 08, 2022. Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies.

Citius Oncology, Inc. trades at a P/E ratio of -3.26, slightly below the S&P 500 average, with a price-to-sales ratio of 19.71 and a price-to-book ratio of 1.32 suggesting the stock is closer to book value. The P/FCF stands at -6.03, also below market averages.

Our AI price prediction model suggests that Citius Oncology, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 11.73%, with price expected at $1.01 by May 25, 2026, within a range of $0.92 to $1.11 3-Month Outlook: Projected rise of 96.9%, reaching $1.78 by August 07, 2026, with a range of $1.32 to $2.03. 1-Year Outlook: Projected loss of -80.09%, with price at $0.18 by May 11, 2027, within a range of $0.00 to $0.00.

Citius Oncology, Inc. (NASDAQ:CTOR) shares are flat 5.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Citius Oncology, Inc. trading at a premium to the broader market with a P/E of -3.26. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $4.50, suggesting 397.79% upside. Our AI forecast model points to short-term strength (11.73% over two weeks), a medium-term rise (96.9% over three months), and a longer-term loss (-80.09% over one year), with expected trading ranges indicating moderate volatility.